Clinical experience with Zarzio® in Europe: what have we learned?

Biosimilars are similar, but non-identical, versions of existing biological drugs for which patents have expired. Despite the rigorous approval process for biosimilars, concerns have been expressed about the efficacy and safety of these products in clinical practice. Biosimilars of filgrastim, based...

Descripción completa

Detalles Bibliográficos
Autores principales: Gascón, Pere, Tesch, Hans, Verpoort, Karl, Rosati, Maria Sofia, Salesi, Nello, Agrawal, Samir, Wilking, Nils, Barker, Helen, Muenzberg, Michael, Turner, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765845/
https://www.ncbi.nlm.nih.gov/pubmed/23903799
http://dx.doi.org/10.1007/s00520-013-1911-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765845/
https://www.ncbi.nlm.nih.gov/pubmed/23903799
http://dx.doi.org/10.1007/s00520-013-1911-7

Ejemplares similares